KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Net Income (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Net Income data on record, last reported at $49.6 million in Q4 2025.

  • For Q4 2025, Net Income rose 339.0% year-over-year to $49.6 million; the TTM value through Dec 2025 reached $127.9 million, up 273.17%, while the annual FY2025 figure was $127.9 million, 273.17% up from the prior year.
  • Net Income reached $49.6 million in Q4 2025 per AMRX's latest filing, up from $18.1 million in the prior quarter.
  • Across five years, Net Income topped out at $49.6 million in Q4 2025 and bottomed at -$240.1 million in Q2 2022.
  • Average Net Income over 5 years is -$11.5 million, with a median of $4.7 million recorded in 2022.
  • The widest YoY moves for Net Income: up 1134.42% in 2023, down 1504.14% in 2023.
  • A 5-year view of Net Income shows it stood at -$20.4 million in 2021, then surged by 71.51% to -$5.8 million in 2022, then crashed by 1504.14% to -$93.3 million in 2023, then soared by 77.77% to -$20.7 million in 2024, then soared by 339.0% to $49.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income were $49.6 million in Q4 2025, $18.1 million in Q3 2025, and $35.6 million in Q2 2025.